Loading clinical trials...
Loading clinical trials...
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER
Conditions
Interventions
avelumab
PLD
Locations
295
United States
Arizona Oncology Associates, PC - HAL
Chandler, Arizona, United States
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona, United States
Arizona Oncology Associates, PC-HAL
Tempe, Arizona, United States
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
Start Date
December 21, 2015
Primary Completion Date
September 19, 2018
Completion Date
July 12, 2022
Last Updated
July 10, 2023
NCT06257264
NCT06964009
NCT06547840
NCT05080946
NCT07498829
NCT06503146
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions